



**Dmitry Osolodkin, PhD**, is a prominent Russian researcher in the fields of medicinal chemistry and chemoinformatics. The main topic of his current research is data-driven antiviral drug discovery. After ten years as a research associate at Lomonosov Moscow State University, which gave him a wide spectrum of experience on the molecular modelling application in different medicinal and biological chemistry problems, he moved to Chumakov FSC R&D IBP RAS in 2015, where he established the Laboratory of Antivirals. The mission of this Laboratory is to integrate virtual and experimental screening approaches with the aim to develop broad-spectrum antiviral drugs. Research highlights include an unified approach to systematization and curation of antiviral activity data, allowing to predict new antiviral scaffolds based on big data analysis, and several lead compounds targeting tick-borne encephalitis virus, other orthoflaviviruses, and SARS-CoV-2. Dr. Osolodkin co-authored more than 77 papers in peer-reviewed journals and 5 patents.